Neurotrophic Keratitis (NK) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Neurotrophic Keratitis Emerging Therapy and TPP Insights

Thelansis's "Neurotrophic Keratitis (NK) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Neurotrophic Keratitis (NK) Overview

Neurotrophic keratitis (NK) is a rare degenerative corneal disease caused by damage to the trigeminal nerve, resulting in reduced corneal sensation, impaired healing, persistent epithelial defects, and, in severe cases, vision-threatening corneal ulceration. For many years, treatment focused on protecting the ocular surface with lubricants, therapeutic contact lenses, and amniotic membrane transplantation without addressing the underlying nerve damage. This changed with the approval of cenegermin, the first recombinant human nerve growth factor approved for NK, which promotes corneal nerve regeneration and healing rather than simply managing complications. It remains the only approved disease-specific therapy, while the same biological approach is being investigated for other ophthalmic conditions using alternative delivery methods. For stakeholders, NK demonstrates how innovation in a rare disease can establish a platform for broader therapeutic development.

Key Highlights

• In Germany, diagnosed Neurotrophic Keratitis (NK) cases are projected to increase from 22,780 in 2025 to 23,993 by 2035.
• Neurotrophic Keratitis is a rare degenerative corneal disease that can lead to persistent epithelial defects, corneal ulcers, and vision loss.
• Delayed diagnosis and limited treatment options continue to pose significant clinical challenges.
• Significant unmet need remains for therapies that promote corneal healing and preserve vision.

Market Overview

• The France Neurotrophic Keratitis market is projected to grow from $22M in 2025 to $40M by 2035.
• Market growth is driven by:
• Increasing adoption of regenerative ophthalmic therapies
• Improved disease awareness and earlier diagnosis
• Future growth will depend on therapies capable of restoring corneal nerve function and achieving sustained corneal healing.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Dompe Farmaceutici S.p.A.
• TearSolutions, Inc.
• Staidson (Beijing) Biopharmaceuticals Co., Ltd.
• ReGenTree, LLC
• Krystal Biotech, Inc.
• Claris Biotherapeutics, Inc.